Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. covers the month of September 2018, specifically dated September 25, 2018. The company is a clinical-stage biopharmaceutical firm headquartered in Montrouge, France, with additional operations in New York. It develops Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform designed for self-administered, non-invasive treatment of food allergies and other immune diseases.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report announcing a corporate event rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document serves solely to announce an upcoming investor presentation.
Guidance, Outlook, and Management Commentary
- Upcoming Event: Susanna Mesa, Chief Business Officer, is scheduled to present at the Cantor Global Healthcare Conference on October 2, 2018, at 9:10 am EST in New York, NY.
- Access: A live webcast and a replay (available within three hours) will be hosted on the company's Investor Relations website.
- Pipeline Status: The company continues ongoing clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development of Viaskin Egg, and a human proof-of-concept study for Viaskin Milk in treating Eosinophilic Esophagitis.
- Risks and Contingencies: No specific risks or contingencies are detailed in this press release excerpt.
Key Facts for Investor Verification
- Verify the date and time of the Cantor Global Healthcare Conference presentation (October 2, 2018, 9:10 am EST).
- Confirm the availability of the live webcast and replay on the official DBV Technologies website.
- Review the latest financial results in the most recent Form 20-F or quarterly report, as this filing contains no financial data.
- Monitor the status of clinical trials for Viaskin Peanut and Viaskin Milk for updates on regulatory milestones.